Akers Biosciences Inc (NASDAQ:AKER) saw a large decline in short interest in the month of December. As of December 29th, there was short interest totalling 194,099 shares, a decline of 63.3% from the December 15th total of 529,598 shares. Based on an average daily trading volume, of 3,936,865 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.9% of the company’s shares are short sold.

Shares of Akers Biosciences (AKER) opened at $0.18 on Friday. Akers Biosciences has a 1 year low of $0.12 and a 1 year high of $2.90. The company has a market cap of $4.58, a P/E ratio of -0.31 and a beta of -0.38.

Akers Biosciences (NASDAQ:AKER) last issued its quarterly earnings results on Wednesday, November 15th. The medical instruments supplier reported ($0.13) EPS for the quarter. Akers Biosciences had a negative return on equity of 94.44% and a negative net margin of 134.31%. The business had revenue of $0.68 million for the quarter.

Separately, ValuEngine upgraded shares of Akers Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, December 1st.

ILLEGAL ACTIVITY WARNING: “Short Interest in Akers Biosciences Inc (AKER) Declines By 63.3%” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/14/short-interest-in-akers-biosciences-inc-aker-declines-by-63-3.html.

About Akers Biosciences

Akers Biosciences, Inc, together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States and internationally. The company’s marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness.

Receive News & Ratings for Akers Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.